Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Ofev Affects Cell Cycle Genes in IPF Fibroblasts, Study Finds
- Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF
- Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says
- Top 10 Pulmonary Fibrosis Stories of 2018
- Ofev Maintains Effectiveness in Advanced IPF Patients, Real-world Study Shows
- Poor Lung Function Before Starting Ofev Seen as Main Reason for Halting Use in UK Real-world Study
- Ofev of Less Benefit to Severe IPF Patients But Those Who Can Stay on Therapy Gain, Study Finds
IPF News:
- Repeated Lung Cancer Surgery in IPF Patients May Worsen Outcomes
- Online ‘Personal Health’ Campaign Aims to Educate and Empower People with Lung Diseases
- Breathing Easier on the Canadian West Coast
- PF Brain Fog Struggles and Solutions
- Aloperine May Protect Against Pulmonary Fibrosis in Mouse Model, Study Suggests
- Yankees’ Bernie Williams Talks About His Father’s Journey With IPF
- 4 Common Coughing Triggers for Idiopathic Pulmonary Fibrosis
Esbriet News:
- Algernon Plans to Test Its Lead Anti-fibrotic Compound in Animal Study of IPF
- Esbriet Extends Long-term Survival, Slows IPF Progression, Real-life Study Reveals
- Real-world Use of Esbriet and Ofev Supports Their Safety and Tolerability, Study Says
- Top 10 Pulmonary Fibrosis Stories of 2018
- Esbriet Extends IPF Patient Survival, Real-world Study Reports
- Nuformix’s NXP002 Candidates Show Potential Against IPF in ‘In-Patient’ Preclinical Model
- No New Safety Concerns with Esbriet, Results from Long-term PASSPORT Study Show
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
- IPF Patients on Esbriet Live Approximately 2.5 Years Longer Than Untreated Patients, Study Finds
- Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says
FDA News:
- FDA Clears Way for First Trials of IPF Treatment Candidate X-165
- Experimental IPF Therapy BBT-877 Gets FDA’s Orphan Drug Status
- Promedior’s Experimental IPF Therapy PRM-151 to Enter Phase 3 Stage
- Top 10 Pulmonary Fibrosis Stories of 2018
- FDA Approves the Launch of Clinical Trials to Assess IPF Candidate BBT-877
- Phase 1 Trial of IPF Candidate Therapy BBT-877 Planned for January
- X-Rx Completes Early Studies on X-165 for Potential IPF Treatment, Supporting IND Application